Chosa Oncology (CHOSA) Q2 2025 earnings summary

Executive summary

• Achieved key progress in clinical validation studies and expanded patient reach, with promising retrospective results in metastatic breast cancer using the DRP® platform for platinum-based therapies.

• Initiated a retrospective validation study in lung cancer, leveraging data from the SPLENDOUR study, with results expected in Q3 2025.

• Extended financial flexibility through a directed share issue and a rights issue, raising a total of 5 MSEK before costs.

Financial highlights

• Other operating income for Q2 2025 was 677 TSEK, compared to 0 in Q2 2024.

• Net result after financial items for Q2 2025 was 2,645 TSEK, up from -1,950 TSEK in Q2 2024.

• Earnings per share for Q2 2025 were 0.037 SEK, compared to -0.32 SEK in Q2 2024.

• Equity ratio as of June 30, 2025, was 88%, down from 91% a year earlier.

• Cash and cash equivalents at June 30, 2025, were 1,876 TSEK, compared to 11,136 TSEK at June 30, 2024.

Outlook and guidance

• Results from the SPLENDOUR lung cancer study are expected to be communicated in Q3 2025.

• Poster presentation of carboplatin data accepted for ESMO Congress in October 2025.

• Ongoing focus on licensing or partnering key assets, including LiPlaCis® and DRP® technologies.